# Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity

> **NCT00197249** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1034 (actual)

## Conditions studied

- Hepatitis A

## Interventions

- **BIOLOGICAL:** Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix

## Key facts

- **NCT ID:** NCT00197249
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-06
- **Final completion:** 2005-11
- **Target enrollment:** 1034 (ACTUAL)
- **Last updated:** 2016-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00197249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00197249, "Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT00197249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*